295 related articles for article (PubMed ID: 24454943)
1. High rate of per oral mecillinam treatment failure in community-acquired urinary tract infections caused by ESBL-producing Escherichia coli.
Søraas A; Sundsfjord A; Jørgensen SB; Liestøl K; Jenum PA
PLoS One; 2014; 9(1):e85889. PubMed ID: 24454943
[TBL] [Abstract][Full Text] [Related]
2. Microbial risk factors for treatment failure of pivmecillinam in community-acquired urinary tract infections caused by ESBL-producing Escherichia coli.
Syre H; Hetland MAK; Bernhoff E; Bollestad M; Grude N; Simonsen GS; Löhr IH
APMIS; 2020 Mar; 128(3):232-241. PubMed ID: 31755584
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for community-acquired urinary tract infections caused by ESBL-producing enterobacteriaceae--a case-control study in a low prevalence country.
Søraas A; Sundsfjord A; Sandven I; Brunborg C; Jenum PA
PLoS One; 2013; 8(7):e69581. PubMed ID: 23936052
[TBL] [Abstract][Full Text] [Related]
4. Mecillinam/clavulanate combination: a possible option for the treatment of community-acquired uncomplicated urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
Lampri N; Galani I; Poulakou G; Katsarolis I; Petrikkos G; Giamarellou H; Souli M
J Antimicrob Chemother; 2012 Oct; 67(10):2424-8. PubMed ID: 22665388
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for community-onset urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
Tüzün T; Sayın Kutlu S; Kutlu M; Kaleli İ
Turk J Med Sci; 2019 Aug; 49(4):1206-1211. PubMed ID: 31385490
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of gram-negative urinary tract infections caused by extended spectrum beta lactamases: pivmecillinam as a treatment option within South Dublin, Ireland.
O'Kelly F; Kavanagh S; Manecksha R; Thornhill J; Fennell JP
BMC Infect Dis; 2016 Nov; 16(1):620. PubMed ID: 27806687
[TBL] [Abstract][Full Text] [Related]
7. Extended-spectrum β-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy.
Meier S; Weber R; Zbinden R; Ruef C; Hasse B
Infection; 2011 Aug; 39(4):333-40. PubMed ID: 21706226
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for community acquired urinary tract infections caused by extended spectrum β-lactamase (ESBL) producing
Zhu FH; Rodado MP; Asmar BI; Salimnia H; Thomas R; Abdel-Haq N
Infect Dis (Lond); 2019; 51(11-12):802-809. PubMed ID: 31429616
[No Abstract] [Full Text] [Related]
9. Plasmid-mediated AmpC beta-lactamase-producing Escherichia coli causing urinary tract infection in the Auckland community likely to be resistant to commonly prescribed antimicrobials.
Drinkovic D; Morris AJ; Dyet K; Bakker S; Heffernan H
N Z Med J; 2015 Mar; 128(1410):50-9. PubMed ID: 25829039
[TBL] [Abstract][Full Text] [Related]
10. Prevalence, antibiotic sensitivity pattern and genetic analysis of extended spectrum beta lactamase producing Escherichia coli and Klebsiella spp among patients with community acquired urinary tract infection in Galle district, Sri Lanka.
Priyadharshana U; Piyasiri LB; Wijesinghe C
Ceylon Med J; 2019 Dec; 64(4):140-145. PubMed ID: 32120467
[TBL] [Abstract][Full Text] [Related]
11. Emerging clinical role of pivmecillinam in the treatment of urinary tract infections caused by Extended Spectrum βeta-lactamase (ESBL) producing Enterobacteriaceae.
Raja NS
Int J Clin Pract; 2019 Sep; 73(9):1-5. PubMed ID: 31243859
[TBL] [Abstract][Full Text] [Related]
12. Pediatric community acquired urinary tract infections due to extended-spectrum beta-lactamase versus non-extended-spectrum beta-lactamase producing bacteria.
Alsubaie MA; Alsuheili AZ; Aljehani MN; Alothman AA; Alzahrani AS; Mohammedfadel HA; Alnajjar AA
Pediatr Int; 2023; 65(1):e15620. PubMed ID: 37735838
[TBL] [Abstract][Full Text] [Related]
13. Comparison of community-onset healthcare-associated and hospital-acquired urinary infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and antimicrobial activities.
Saltoglu N; Karali R; Yemisen M; Ozaras R; Balkan II; Mete B; Tabak F; Mert A; Hondur N; Ozturk R
Int J Clin Pract; 2015 Jul; 69(7):766-70. PubMed ID: 25683907
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.
Arslan H; Azap OK; Ergönül O; Timurkaynak F;
J Antimicrob Chemother; 2005 Nov; 56(5):914-8. PubMed ID: 16174685
[TBL] [Abstract][Full Text] [Related]
15. Urinary tract infection caused by extended-spectrum β-lactamase-producing bacteria: Risk factors and antibiotic resistance.
Albaramki JH; Abdelghani T; Dalaeen A; Khdair Ahmad F; Alassaf A; Odeh R; Akl K
Pediatr Int; 2019 Nov; 61(11):1127-1132. PubMed ID: 31206219
[TBL] [Abstract][Full Text] [Related]
16. Clinical and bacteriological effects of pivmecillinam for ESBL-producing Escherichia coli or Klebsiella pneumoniae in urinary tract infections.
Jansåker F; Frimodt-Møller N; Sjögren I; Dahl Knudsen J
J Antimicrob Chemother; 2014 Mar; 69(3):769-72. PubMed ID: 24107388
[TBL] [Abstract][Full Text] [Related]
17. Worrisome high frequency of extended-spectrum beta-lactamase-producing Escherichia coli in community-acquired urinary tract infections: a case-control study.
Castillo-Tokumori F; Irey-Salgado C; Málaga G
Int J Infect Dis; 2017 Feb; 55():16-19. PubMed ID: 27979787
[TBL] [Abstract][Full Text] [Related]
18. Reversion of High-level Mecillinam Resistance to Susceptibility in Escherichia coli During Growth in Urine.
Thulin E; Thulin M; Andersson DI
EBioMedicine; 2017 Sep; 23():111-118. PubMed ID: 28855073
[TBL] [Abstract][Full Text] [Related]
19. Does urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli show same antibiotic resistance when it recurs?
Ahn ST; Kim SW; Kim JW; Park HS; Moon DG; Oh MM
J Infect Chemother; 2019 Jul; 25(7):498-502. PubMed ID: 30852104
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for community acquired pediatric urinary tract infection with extended-spectrum-β-lactamase Escherichia coli - A case-control study.
Collingwood JD; Wang L; Aban IB; Yarbrough AH; Boppana SB; Dangle PP
J Pediatr Urol; 2023 Feb; 19(1):129.e1-129.e7. PubMed ID: 36344365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
